EU HTA Bodies, Payers Look At Ways To Fill Evidence Gaps In Early Access Schemes
Executive Summary
While the German pricing and reimbursement authority continues to argue that there is insufficient comparative data for drugs that are granted conditional marketing authorization, health technology assessment bodies and payers in the EU generally agree that they need to find innovative solutions to work around these evidence gaps.